How do LMIC contexts fit into global evidence hierarchies — and when does a globally endorsed finding break on contact with India's specific political, fiscal, and demographic realities?
India is not an average LMIC
Global evidence hierarchies — WHO guidelines, Cochrane reviews, GBD estimates, World Bank benchmarks — are produced at a scale of aggregation that is useful for setting global direction and deeply insufficient for informing a specific Indian state's health financing decision. India is simultaneously: the world's most populous country, a federal system with 28 states that function as near-independent health economies, the home of a 90% informal sector, a middle-income country by GNI per capita that contains the world's largest concentration of absolute poverty, and a country producing an increasingly sophisticated domestic health economics evidence base through HTAIn, NHA, and NSSO that rivals any LMIC in methodological rigour.
Understanding where India sits in global evidence hierarchies — and where it appropriately challenges them — is not academic. It determines which global findings can be cited in a WHO India brief, which require explicit India-specific caveats, and which must be replaced by domestic evidence entirely.
The global evidence hierarchy — and where India fits
L1
Global systematic reviews and meta-analyses
Cochrane, Campbell, Lancet commissions, WHO guidelines. Highest methodological rigour but lowest India-specificity. Typically use 10% household consumption as the catastrophic expenditure threshold — which WHO India should apply cautiously given India's specific consumption distribution.
India use: Cite for direction of effect and existence of evidence. Never cite aggregate pooled estimates as India-specific without checking whether India data is in the pool and what it shows separately.
L2
LMIC comparative studies and regional evidence
World Bank working papers, regional WHO analyses, LMIC-focused journals (Health Policy and Planning, BMJ Global Health). More contextually relevant but still often aggregate across diverse health systems with little in common beyond income classification.
India use: Cite when India is explicitly included in the sample. Flag when evidence is from sub-Saharan Africa or South-East Asia only — comparable in income classification but not in federal structure, insurance landscape, or informal economy scale.
L3
India national evidence
NSSO/NSO surveys, NHA, NFHS, HMIS, HTAIn assessments, peer-reviewed India-specific studies. Highest India-relevance; methodological quality varies. HTAIn assessments use a defined reference case with standardised methods — treat these as gold standard for cost-effectiveness evidence in India.
India use: Always prefer over LMIC extrapolation when available. Note the year of data collection — NSSO rounds and NHA releases may be 2–4 years old by the time a brief is written.
L4
State-level evidence
State NHA accounts, state health department reports, state-specific PM-JAY evaluations, academic studies on specific states. Highest granularity but most variable in quality and rarely peer-reviewed. Kerala, Tamil Nadu, and Maharashtra have more developed state health information systems than most other states.
India use: Essential for state-specific briefs. When national-level evidence and state-level evidence diverge, the divergence is the finding — it signals state heterogeneity that a national policy recommendation must account for.
L5
Expert opinion and programme data
Key informant interviews, programme monitoring data, WHO country office assessments, MoHFW internal reports. Lowest in formal evidence hierarchy but often the most current and most politically contextualised. Programme data from the NHA is an exception — methodologically robust and regularly updated.
India use: Valuable for triangulation and political feasibility assessment. Never cite as the primary evidence base for a cost-effectiveness or financial protection finding.
Six places where global evidence breaks on India
These are the structural mismatches between global health financing evidence and India's reality that recur most frequently in WHO India briefs. Each one requires explicit acknowledgment when global evidence is cited:
Federal structure
Health is a state subject
India's constitution makes health primarily a state responsibility. A national-level intervention finding cannot be extrapolated to a specific state without accounting for that state's fiscal space, infrastructure, and political economy. A finding true for Kerala may be false for Bihar.
→ Always ask: which states does this apply to, and what explains the variation?
Informal economy scale
90% informal workforce
Most global health insurance evidence assumes some formal employment link for enrolment and premium collection. India's 90% informal sector means that employer-linked insurance models and formal payroll-based schemes are inapplicable to the vast majority of the target population for UHC expansion.
→ Any insurance evidence must specify whether enrolment mechanism is compatible with informal workers.
Fragmented coverage
Not zero vs. covered
Global evidence often compares insured vs. uninsured. India's counterfactual is not "no coverage" — it is a complex mix of ESIS, CGHS, state government schemes, PM-JAY, and out-of-pocket care. Incremental benefit estimates from global studies overstate PM-JAY's marginal impact.
→ The correct comparator for any India brief is the existing coverage mix, not zero coverage.
Provider landscape
Private sector dominance
Over 70% of outpatient care and 60% of inpatient care in India is provided by private facilities. Most global health insurance models assume public provision as the default. India's private-dominant landscape creates moral hazard, adverse selection, and claims fraud dynamics that most global models do not capture.
→ Evidence on insurance from countries with public-dominant provider landscapes does not transfer cleanly.
Expenditure measurement
OOP definitions diverge
Global studies use diverse thresholds for catastrophic expenditure — 10% of household consumption, 25%, 40% of non-food expenditure. India's NHA uses its own methodology. Comparing a globally-pooled 28% OOP reduction figure to India's NHA-measured baseline requires explicit threshold reconciliation.
→ Always check whether global studies and India data use the same OOP definition before comparing.
Demographic scale
India's internal diversity exceeds many regions
The health financing gap between India's highest- and lowest-performing states (Kerala vs. Uttar Pradesh) is larger than the gap between many pairs of separate countries. A finding true for "India" may describe neither high-performing nor low-performing states accurately.
→ National aggregate findings require explicit statement of the state-level variance they conceal.
When global evidence is and is not usable for India
Evidence type
Transferability to India
Conditions for use
RCT on insurance scheme in comparable LMIC (Kenya, Rwanda)
Conditional
Usable for direction of effect if intervention design is comparable. Not usable for effect size without adjustment. Must note differences in provider landscape, informal economy, and existing coverage.
Global meta-analysis on community health insurance
Low
Usable only if India studies are in the pool and reported separately. Check whether pooled estimate is driven by sub-Saharan African schemes structurally incompatible with India's context.
WHO or World Bank global policy recommendation
Conditional
Usable as normative framing. Not usable as cost-effectiveness evidence without India-specific data. Global recommendations are produced at a level of generality that explicitly requires national adaptation.
HTAIn cost-effectiveness assessment
High
Designed specifically for India. Produced using the India reference case. Preferred over any LMIC extrapolation for cost-effectiveness findings. Check publication year — assessment may predate current PM-JAY scale.
India NHA or NSSO financial protection data
High
Gold standard for India OOP and financial protection baseline. Check round year — NSSO rounds are periodic and NHA releases lag by 2–3 years. Use latest available round explicitly dated.
Global GBD disease burden estimate
Conditional
Usable for burden framing. IHME India estimates are increasingly granular to state level. Prefer India NFHS and HMIS for specific disease burden claims where available — GBD uses modelling that may diverge from India's own surveillance data.
High-income country insurance model (Germany, Netherlands, South Korea)
Low
Not transferable for cost or effect estimates. Potentially useful as a structural model for universal coverage architecture — but the implementation pathway through India's informal economy, federal structure, and private provider landscape requires complete redesign.
Stress-test a finding for India transferability
🌊 India transferability stress-test
Paste a finding from any global or LMIC health financing study you are considering citing in a WHO India brief. Describe where it came from. The stress-test will assess transferability against India's six friction points and return a structured verdict on how it can and cannot be used.
The finding you want to citeState it exactly as you plan to use it in the brief
Source countries / settingsWhere was this evidence produced?
How you plan to use itIn which section and for what purpose?
🌊 India transferability verdict
🎯 Key takeaway
Global evidence is the starting point, not the destination. For WHO India health financing briefs, the journey from a globally endorsed finding to a citable India recommendation requires passing through six friction points: federal structure, informal economy scale, fragmented existing coverage, private provider dominance, expenditure measurement divergence, and India's internal demographic heterogeneity. HTAIn assessments and NHA data are the India gold standard and should always be preferred over LMIC extrapolation when they exist. When they do not exist, global evidence can be cited — with explicit acknowledgment of the transferability assumptions being made. The stress-test in this session is the last quality gate before a global finding enters a WHO India brief. Session 5 closes the curriculum by asking the largest question: what does it mean to be an integrator of health evidence at this scale?